Verrica Pharmaceuticals (VRCA) Stock Statistics & Valuation Metrics

Verrica Pharmaceuticals has a market cap or net worth of $57.72M. The enterprise value is $70.56M.

Verrica Pharmaceuticals has 9,250,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Verrica Pharmaceuticals’s return on equity (ROE) is 7.77 and return on invested capital (ROIC) is -167.33%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Verrica Pharmaceuticals had revenue of 7.57M and earned -76.58M in profits. Earnings per share was -14.80.

In the last 12 months, operating cash flow was -509.00K and capital expenditures 0.00, giving a free cash flow of -509.00K billion.

Verrica Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Verrica Pharmaceuticals upcoming earnings date is Aug 12, 2025, TBA (Confirmed).

Verrica Pharmaceuticals as a current ratio of 1.76, with Debt / Equity ratio of -78.73%

In the past 12 months, Verrica Pharmaceuticals has paid 0.00 in taxes.

Verrica Pharmaceuticals EV to EBITDA ratio is -0.54, with an EV/FCF ratio of -0.59.

Verrica Pharmaceuticals has $29.59M in cash and marketable securities with $42.43M in debt, giving a net cash position of $12.84M billion.

Gross margin is 71.79%, with operating margin of -871.25%, and net profit margin of -1012.15%.

The average price target for Verrica Pharmaceuticals is $35.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy